Providence, RI--(BUSINESS WIRE)--Beech Tree Labs, Inc., announced today that the FDA has approved its IND for a 180 patient Phase 1/2a clinical evaluation of BTL-TML001, a novel therapeutic agent for treating acute influenza virus infections.
In the United States it is estimated that outbreaks of seasonal flu incur annual costs of more than $12 billion with a mortality rate of over 36,000 people. In the case of a pandemic, estimated annual costs would range from $71 to $167 billion for attack rates of 15-35 percent of the population.
Beech Tree Labs is a privately held biopharmaceutical company specializing in discovery and early-stage development. It is a leader in resonant molecular signaling technology and holds a number of patents on other potential therapeutics.